Delayed radioprotection by NFκB-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs

Radiation Research

Volumn 162, Issue 5, 2004, Pages 536-546

  Murley, Jeffrey S ^a   Kataoka, Yasushi ^a   Cao, Dingcai ^a   Li, Jian Jian ^b   Oberleyd, Larry W ^c   Grdina, David J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 3 [(4 METHYLPHENYL)SULFONYL] 2 PROPENENITRILE; ACETYLCYSTEINE; AMIFOSTINE; CAPTOPRIL; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; MESNA; SERINE; SUPEROXIDE DISMUTASE; THIOL DERIVATIVE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CYSTEAMINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PROTECTIVE AGENT; RADIOPROTECTIVE AGENT;

ANIMAL CELL; ARTICLE; CELL KILLING; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RADIATION PROTECTION; SURVIVAL; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; CHEMISTRY; DNA DAMAGE; DOSE RESPONSE; GENETIC TRANSFECTION; METABOLISM; MUTATION; PHOSPHORYLATION; PLASMID; RADIATION RESPONSE; TIME; TUMOR CELL LINE;

ACETYLCYSTEINE; AMIFOSTINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOTTING, WESTERN; CAPTOPRIL; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; I-KAPPA B PROTEINS; MERCAPTOETHYLAMINES; MESNA; MICE; MUTATION; NF-KAPPA B; PHOSPHORYLATION; PLASMIDS; PROTECTIVE AGENTS; RADIATION-PROTECTIVE AGENTS; SERINE; SULFHYDRYL COMPOUNDS; SUPEROXIDE DISMUTASE; TIME FACTORS; TRANSFECTION;

EID: 10044231865     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3256     Document Type: Article

References (40)

1. M. L. Hensley, L. M. Schuchter, C. Lindley, N. J. Meropol, G. I. Cohen, G. Broder, W. J. Gradishar, D. M. Green, R. J. Langdon and E. P. Winer, American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 17, 3333-3355 (1999).
2. C. K. Sen and L. Packer, Antioxidant and redox regulation of gene transcription. FASEB J. 10, 709-720 (1996).
3. L. Flohe, R. Brigelius-Flohe, C. Saliou, M. G. Traber and L. Packer, Redox regulation of NFκB activation. Free Radic. Biol. Med. 22, 1115-1126 (1997).
4. J. S. Murley, A. Constantinou, N. S. Kamath and D. J. Grdina, WR1065, an active metabolite of amifostine, affects phosphorylation of topoisomerase IIα leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Prolif. 30, 283-294 (1997).
5. J. S. Murley, Y. Kataoka, D. E. Hallahan, J. C. Roberts and D. J. Grdina, Activation of NFκB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic. Biol. Med. 30, 1426-1439 (2001).
6. K. C. Das, Y. Lewis-Molock and C. W. White, Activation of NFκB and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells. Am. J. Physiol. 269, L588-L602 (1995).
7. K. C. Das, Y. Lewis-Molock and C. W. White, Thiol modulation of TNFα and IL-1 induced MnSOD gene expression and activation of NFκB. Mol. Cell. Biochem. 148, 45-57 (1995).
8. J. Antras-Ferry, K. Maheo, M. Chevanne, M. P. Dubos, F. Morel, A. Guillouzo, P. Cillard and J. Cillard, Oltipraz stimulates the transcription of the manganese superoxide dismutase gene in rat hepatocytes. Carcinogenesis 18, 2113-2117 (1997).
9. I. Fridovich, Superoxide radical and superoxide dismutases. Annu. Rev. Biochem. 64, 97-112 (1995).
10. K. Hirose, D. L. Longo, J. J. Oppenheim and K. Matsushima, Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. FASEB J. 7, 361-368 (1993).
11. J. Sun, Y. Chen, M. Li and Z. Ge, Role of antioxidant enzymes on ionizing radiation resistance. Free Radic. Biol. Med. 24, 586-593 (1998).
12. G. H. W. Wong and D. V. Goeddel, Induction of manganous superoxide dismutase by tumor necrosis factor: Possible protective mechanism. Science 242, 941-944 (1988).
13. S. Motoori, H. J. Majima, M. Ebara, H. Kato, F. Hirai, S. Kakinuma, C. Yamaguchi, T. Ozawa, T. Nagano and H. Saisho, Overexpression of mitochondrial manganese superoxide dismutase protects against radiation-induced cell death in the human hepatocellular carcinoma cell line HLE. Cancer Res. 61, 5382-5388 (2001).
14. G. H. W. Wong, Protective roles of cytokines against radiation: induction of mitochondrial MnSOD. Biochim. Biophys. Acta 1271, 205-209 (1995).
15. M. W. Epperly, J. E. Gretton, C. A. Sikora, M. Jefferson, M. Bernarding, S. Nie and J. S. Greenberger, Mitochondrial localization of superoxide dismutase is required for decreasing radiation-induced cellular damage. Radiat. Res. 160, 568-578 (2003).
16. J. S. Greenberger, V. E. Kagan, L. Pearce, G. Boriseniao, Y. Tyurina and M. W. Epperly, Modulation of redox signal transduction pathways in the treatment of cancer. Antioxid. Redox Signal. 3, 347-359 (2001).
17. M. W. Epperly, C. J. Epstein, E. L. Travis and J. S. Greenberger, Decreased pulmonary radiation resistance of manganese superoxide dismutase (MnSOD) deficient mice is corrected by human MnSOD plasmid/liposome (SOD2-PL) intratracheal gene therapy. Radiat. Res. 154, 365-374 (2000).
18. M. W. Epperly, S. Defilippi, C. Sikora, J. Gretton, K. Kalend and J. S. Greenberger, Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation. Gene Ther. 7, 1011-1018 (2000).
19. M. W. Epperly, J. A. Bray, S. Krager, L. A. Berry, W. Gooding, J. F. Engelhardt, R. Zwacka, E. Travis and J. S. Greenberger, Intra-tracheal injection of adenovirus containing the human MnSOD transgene protects athymic nude mice from irradiation-induced organizing alveolitis. Int. J. Radiat. Oncol. Biol. Phys. 43, 169-181 (1999).
20. M. W. Epperly, J. A. Bray, S. Krager, R. Zwacka, J. Engelhardt, E. Travis and J. S. Greenberger, Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gene Ther. 5, 196-208 (1998).
21. C. Danel, S. C. Erzurum, P. Prayssac, N. T. Eissa, R. G. Crystal, P. Herve, B. Baudet, M. Mazmanian and P. Lemarchand, Gene therapy for oxidant injury-related diseases: Adenovirus-mediated transfer of superoxide dismutase and catalase cDNAs protects against hyperoxia but not against ischemia-reperfusion lung injury. Hum. Gene Ther. 9, 1487-1496 (1998).
22. J. S. Murley, Y. Kataoka, C. J. Weydert, L. W. Oberley and D. J. Grdina, Delayed cytoprotection after enhancement of SOD2 (Mn-SOD) gene expression in SA-NH mouse sarcoma cells exposed to WR1065, the active metabolite of amifostine. Radiat. Res. 158, 101-109 (2002).
23. X. Chen, B. Shen, L. Xia, A. Khaletzkiy, D. Chu, J. Y. Wong and J. J. Li, Activation of nuclear factor kappa B in radioresistance of TP53-inactive human keratinocytes. Cancer Res. 62, 1213-1221 (2002).
24. S. T. Whiteside, M. K. Ernst, O. LeBail, C. Laurent-Winter, N. Rice and A. Israel, N- and C- terminal sequences control degradation of MAD3/IκBα in response to inducers of NFκB activity. Mol. Cell. Biol. 15, 5339-5345 (1995).
25. D. J. Grdina, N. Shigematsu, P. Dale, G. L. Newton, J. A. Aguilera and R. C. Fahey, Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 16, 767-774 (1995).
26. M. M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72, 248-254 (1978).
27. U. K. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685 (1970).
28. J. W. Pierce, R. Schoenleber, G. Jesmok, J. Best, S. A. Moore, T. Collins and M. E. Gerritsen, Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecular expression show anti-inflammatory effects in vivo. J. Biol. Chem, 272, 21096-21103 (1997).
29. Y. Xu, K. K. Kiningham, M. N. Devalaraja, C. C. Yeh, H. Majima, E. J. Kasarskis and D. K. St. Clair, An intronic NFκB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-α and interleukin 1β. DNA Cell Biol. 18, 709-722 (1999).
30. A. Hoffmann, A. Levchenko, M. L. Scott and D. Baltimore, The IκB-NFκB signaling module: Temporal control and selective gene activation. Science 298, 1241-1245 (2002).
31. C. Savoye, C. Swenberg, S. Hugot, D. Sy, R. Sabattier, M. Charlier and M. Spotheim-Maurizot, Thiol WR1065 and disulphide WR33278, two metabolites of the drug Ethyol (WR2721), protect DNA against fast neutron-induced strand breakage. Int. J. Radiat. Biol. 71, 193-202 (1997).
32. L. Tretter, E. Ronai, G. Szabados, R. Hermann, A. Ando and I. Horvath, The effect of the radioprotector WR2721 and WR1065 on mitochondrial peroxidation. Int. J. Radiat. Biol. 57, 467-478 (1990).
33. K. Mertsch, T. Grune, S. Kunstmann, B. Wiesner, A. M. Ladhoff, W. G. Siems, R. F. Haseloff and I. E. Blasig, Protective effects of the thiophosphate amifostine (WR2721) and a lazaroid (U83836E) on lipid peroxidation in endothelial cells during hypoxia/reoxygenation. Biochem. Pharmacol. 56, 945-954 (1998).
34. D. J. Grdina, Y. Kataoka and J. S. Murley, Amifostine: Mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol. Drug Interact. 16, 237-279 (2000).
35. D. J. Grdina, J. S. Murley and Y. Katoaka, Radioprotectants: Current status and new directions. Oncology 63 (Suppl.), 2-10 (2002).
36. D. P. Bicket, Using ACE inhibitors appropriately. Am. Fam. Physician 66, 461-468 (2002).
37. C. R. Culy and C. M. Spencer, Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61, 641-684 (2001).
38. C. N. Andreassen, C. Grau and J. C. Lindegaard, Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy. Semin. Radiat. Oncol. 13, 62-72 (2003).
39. D. J. Grdina, Y. Kataoka, J. S. Murley, N. Hunter, R. R. Weichselbaum and L. Milas, Inhibition of spontaneous metastases formation by amifostine. Int. J. Cancer 97, 135-141 (2002).
40. A. F. List, Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. Semin. Oncol. 2, 61-65 (1999).